About Asahi Kasei

Asahi Kasei Pharma America (AKP America) is a U.S. biotechnology company that is a wholly-owned subsidiary of Asahi Kasei Pharma Corp. Our lead product, ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), is a late-stage biologic drug candidate being developed for severe sepsis with coagulopathy.

Our management team brings a unique combination of corporate development, global drug development and strategic alliance experience.

To assist AKP America in the development and commercialization of ART 123, we have recruited an ART 123 Program Advisory Board, consisting of the finest research minds in sepsis, critical care and hematology.

clinicaltrials.gov: Safety and Efficacy Study of ART-123 in the Treatment of Severe Sepsis With Coagulopathy